Appendix Table D6Fracture Rates in Bisphosphonate Trials Only Included In Sensitivity Analyses

TrialIntervention Duration Baseline BMD Baseline fractureRadiologically confirmed fracture incidence?Vertebral fractureNonvertebral fractureHip fracture
Active treatment vs. placebo Relative risk (95% CI)Active treatment vs. placebo Relative risk (95% CI)Active treatment vs. placebo Relative risk (95% CI)
Bisphosphonates
Alendronate
Bone et al, 199738Alendronate 5 mg
2 years
T-score: −3.1
Previous vertebral fracture: 37%
Yes4/93 (4%) vs. 6/91 (7%)
RR 0.65 (0.19 to 2.24)
9/93 (10%) vs. 16/91 (18%)
RR 0.55 (0.26 to 1.18)
NR
Greenspan et al, 199846Alendronate 5–10 mg 2.5 years
T-score: −4.3
Unknown prior fracture
NoNot assessed3/60 (5%) vs. 1/60 (2%)
RR 3.00 (0.32 to 28)
0/60 (0%) vs. 1/60 (2%)
RR 0.33 (0.01 to 8.02)
Liberman et al, 199547Alendronate 5 or 10 mg for 3 years, or 20 mg for two years and 5 mg for 1 year
T-score: −3.1
Previous vertebral fracture: 21%
Yes17/526 (3%) vs. 22/355 (6%)
RR 0.52 (0.28 to 0.97)
45/597 (8%) vs. 38/397 (10%)
RR 0.79 (0.52 to 1.19)
1/597 (0.2%) vs. 3/397 (1%)
RR 0.22 (0.02 to 2.12)
Etidronate
Ishida et al, 200440Cyclical etidronate 200 mg/day
2 years
T-score: −1.9
Previous vertebral fracture: 31%
Yes8/66 (12%) vs. 17/66 (26%)
RR 0.47 (0.22 to 1.01)
1/66 (2%) vs. 3/66 (5%)
RR 0.33 (0.04 to 3.12)
0/66 (0%) vs. 1/66 (2%)
RR 0.33 (0.01 to 8.04)
Montessori et al, 199748Cyclical etidronate 400 mg/day
3 years
T-score: −3.4
Previous vertebral fracture: 36%
Yes0/37 (0%) vs. 3/34 (9%)
RR 0.13 (0.01 to 2.46)
NR0/39 (0%) vs. 0/39 (0%)
RR not estimable
Risedronate
Fogelman et al, 200045Risedronate 5 mg/day
2 years
T-score: −2.9
Previous vertebral fracture: 30%
Yes8/112 (7.1%) vs. 17/125 (14%)*
RR 0.53 (0.24 to 1.17)
7/140 (5%) vs. 13/144 (9%)*
RR 0.55 (0.23 to 1.35)
Not reported

Abbreviations: BMD = bone mineral density; CI = confidence interval; NR = not reported; RR = relative risk.

*

Intention-to-treat results not reported (sample sizes 180 for risedronate and 177 for placebo).

Intention-to-treat results not reported (sample sizes 180 for risedronate and 177 for placebo).

From: Appendix D, Appendix Tables

Cover of Screening for Osteoporosis
Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation [Internet].
Evidence Syntheses, No. 77.
Nelson HD, Haney EM, Chou R, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.